Study Stopped
Unable to recruit resaerch staff for study
A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding
1 other identifier
observational
N/A
0 countries
N/A
Brief Summary
Urinary incontinences is a highly prevalent and distressing condition which has a significant impact on health related quality of life in millions of women worldwide. Of all women with incontinence, 90% will have overactive bladder symptoms (OAB), and 50% will have detrusor overactivity (DO) on cystometry. The overactive bladder syndrome is defined by the International Continence society as "Urinary urgency, with or without urge incontinence, usually with frequency and nocturia if there is a no infection or proven pathology" (Abrams et al 2002) Initial management of OAB and DO consists of conservative measures such as altering fluid intake, bladder retraining and drug therapy. The next step consists of interventions such as cystoscopy and urethral dilatation, on the basis that it will allow intrinsic bladder problems such as interstitial cystitis to excluded, excluded, and may confer a symptomatic benefit. The original study showed no benefit of urethral dilatation versus no dilatation at 6 months follow up (Duckett 2007). The investigators do not know the natural history of patients with voiding dysfunction. Therefore reviewing their symptoms will give a better idea of what happens to these patients symptoms over time.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Aug 2016
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 11, 2014
CompletedFirst Posted
Study publicly available on registry
November 21, 2014
CompletedStudy Start
First participant enrolled
August 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedOctober 17, 2016
October 1, 2016
4 months
November 11, 2014
October 13, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
ICIQ-Fluts questionnaire
To identify if there is any long term benefit from urethral dilatation over cystoscopy alone. Their baseline symptoms will be assessed and compared to those identified at baseline in the previous study.
3 years
Secondary Outcomes (3)
King's Health Questionnaire
3 years
Urgency Perception Scale Questionnaire
3 years
Uroflowmetry
3 years
Study Arms (2)
Cystoscopy Alone
Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.
Cystoscopy & Urethral Dilatation
Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.
Interventions
Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
Eligibility Criteria
Entry to the study will be offered to all women previously recruited into the original randomised controlled trial. This study is a 3 year follow up of a randomised controlled trial. Patients will be sent a letter offering a review appointment.
You may qualify if:
- Significant Overactive Bladder Symptoms
- Based on scoring 1 or 2 on the Urgency Perception Scale
- On the symptoms domain of the KHQ
- More than 8 voids per day on frequency volume chart +/- 2 or more episodes of nocturia
- Pressure flow studies demonstrate a maximum flow rate of less than 15ml on a minimum voided volume of 200ml with a high or normal detrusor pressure at maximum flow or post-void residual of 200ml or over
- Patients must be able to give informed consent for the study.
You may not qualify if:
- Presence of concurrent urodynamic stress incontinence.
- Patients with bladder pathology or haematuria of unknown origin.
- Patients with neurological disorders (as these may affect voiding).
- Symptomatic pelvic organ prolapse requiring intervention
- Patients with bladder pathology (including urinary tract infection) or haematuria of unknown origin
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78. doi: 10.1002/nau.10052. No abstract available.
PMID: 11857671RESULTDuckett JR, Basu M. The predictive value of preoperative pressure-flow studies in the resolution of detrusor overactivity and overactive bladder after tension-free vaginal tape insertion. BJU Int. 2007 Jun;99(6):1439-42. doi: 10.1111/j.1464-410X.2007.06842.x. Epub 2007 Apr 5.
PMID: 17419703RESULTMasarani M, Willis RG. Urethral dilatation in women: urologists' practice patterns in the UK. Ann R Coll Surg Engl. 2006 Sep;88(5):496-8. doi: 10.1308/003588406X114884.
PMID: 17002859RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jonathan RA Duckett, FRCOG, MBChB
Medway Maritime Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Consultant Gynaecologist and Obstetrician
Study Record Dates
First Submitted
November 11, 2014
First Posted
November 21, 2014
Study Start
August 1, 2016
Primary Completion
December 1, 2016
Study Completion
December 1, 2016
Last Updated
October 17, 2016
Record last verified: 2016-10